The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.
 
Sehhoon Park
No Relationships to Disclose
 
Hyun Ae Jung
Consulting or Advisory Role - AIMEDBIO; Guardant Health; Yuhan
Research Funding - Yuhan
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Junhun Cho
No Relationships to Disclose
 
Kyungmi Yang
No Relationships to Disclose
 
Dongryul Oh
No Relationships to Disclose
 
Yong Chan Ahn
No Relationships to Disclose
 
Eun-hye Kim
No Relationships to Disclose
 
Nayeon Choi
No Relationships to Disclose
 
Han-Sin Jeong
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN